Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-04-06
2000-10-10
Borin, Michael
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 17, 514 18, 514169, 514182, 424 9464, 930280, 930300, A61K 3807, A61K 3808, A61K 3848
Patent
active
06130204&
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
In 1994 cancer of the prostate gland is expected to be diagnosed in 200,000 men in the U.S. and 38,000 American males will die from this disease (Garnick, M. B. (1994). The Dilemmas of Prostate Cancer. Scientific American, April:72-81). Thus, prostate cancer is the most frequently diagnosed malignancy (other than that of the skin) in U.S. men and the second leading cause of cancer-related deaths (behind lung cancer) in that group.
Prostate specific Antigen (PSA) is a single chain 33 kDa glycoprotein that is produced almost exclusively by the human prostate epithelium and occurs at levels of 0.5 to 2.0 mg/ml in human seminal fluid (Nadji, M., Taber, S. Z., Castro, A., et al. (1981) Cancer 48:1229; Papsidero, L., Kuriyama, M., Wang, M., et al. (1981). JNCI 66:37; Qui, S. D., Young, C. Y. F., Bihartz, D. L., et al. (1990), J. Urol. 144:1550; Wang, M. C., Valenzuela, L. A., Murphy, G. P., et al. (1979). Invest. Urol. 17:159). The single carbohydrate unit is attached at asparagine residue number 45 and accounts for 2 to 3 kDa of the total molecular mass. PSA is a protease with chymotrypsin-like specificity (Christensson, A., Laurell, C. B., Lilja, H. (1990). Eur. J. Biochem. 194:755-763). It has been shown that PSA is mainly responsible for dissolution of the gel structure formed at ejaculation by proteolysis of the major proteins in the sperm entrapping gel, Semenogelin I and Semenogelin II, and fibronectin (Lilja, H. (1985). J. Clin. Invest. 76:1899; Lilja, H., Oldbring, J., Rannevik, G., et al. (1987). J. Clin. Invest. 80:281; McGee, R. S., Herr, J. C. (1988). Biol. Reprod. 39:499). The PSA mediated proteolysis of the gel-forming proteins generates several soluble Semenogelin I and Semenogelin II fragments and soluble fibronectin fragments with liquefaction of the ejaculate and release of progressively motile spermatoza (Lilja, H., Laurell, C. B. (1984). Scand. J. Clin. Lab. Invest. 44:447; McGee, R. S., Herr, J. C. (1987). Biol. Reprod. 37:431). Furthermore, PSA may proteolytically degrade IGFBP-3 (insulin-like growth factor binding protein 3) allowing IGF to stimulate specifically the growth of PSA secreting cells (Cohen et al., (1992) J. Clin. Endo. & Meta. 75:1046-1053).
PSA complexed to alpha 1-antichymotrypsin is the predominant molecular form of serum PSA and may account for up to 95% of the detected serum PSA (Christensson, A., Bjork, T., Nilsson, O., et al. (1993). J. Urol. 150:100-105; Lilja, H., Christensson, A., Dahlen, U. (1991). Clin. Chem. 37:1618-1625; Stenman, U. H., Leinoven, J., Alfthan, H., et al. (1991). Cancer Res. 51:222-226). The prostatic tissue (normal, benign hyperplastic, or malignant tissue) is implicated to predominantly release the mature, enzymatically active form of PSA, as this form is required for complex formation with alpha 1-antichymotrypsin (Mast, A. E., Enghild, J. J., Pizzo, S. V., et al. (1991). Biochemistry 30:1723-1730; Perlmutter, D. H., Glover, G. I., Rivetna, M., et al. (1990). Proc. Natl. Acad. Sci. USA 87:3753-3757). Therefore, in the microenvironment of prostatic PSA secreting cells the PSA is believed to be processed and secreted in its mature enzymatically active form not complexed to any inhibitory molecule. PSA also forms stable complexes with alpha 2-macroglobulin, but as this results in encapsulation of PSA and complete loss of the PSA epitopes, the in vivo significance of this complex formation is unclear. A free, noncomplexed form of PSA constitutes a minor fraction of the serum PSA (Christensson, A., Bjork, T., Nilsson, O., et al. (1993). J. Urol. 150:100-105; Lilja, H., Christensson, A., Dahlen, U. (1991). Clin. Chem. 37:1618-1625). The size of this form of serum PSA is similar to that of PSA in seminal fluid (Lilja, H., Christensson, A., Dahlen, U. (1991). Clin. Chem. 37:1618-1625) but it is yet unknown as to whether the free form of serum PSA may be a zymogen; an internally cleaved, inactive form of mature PSA; or PSA manifesting enzyme activity. However, it seems unlikely that the free form of serum PSA manifests enzy
REFERENCES:
patent: 4277466 (1981-07-01), Trouet
patent: 4296105 (1981-10-01), Baurain et al.
patent: 4388305 (1983-06-01), Trouet et al.
patent: 4446122 (1984-05-01), Chu et al.
patent: 4703107 (1987-10-01), Monsigny et al.
patent: 4753984 (1988-06-01), Delmotte et al.
patent: 4828831 (1989-05-01), Hannart et al.
patent: 4870162 (1989-09-01), Trouet et al.
patent: 5024835 (1991-06-01), Rao et al.
patent: 5030620 (1991-07-01), Hannart et al.
patent: 5116615 (1992-05-01), Gokcen et al.
patent: 5220001 (1993-06-01), Ok et al.
patent: 5227471 (1993-07-01), Wright, Jr.
patent: 5288612 (1994-02-01), Griffin et al.
patent: 5314996 (1994-05-01), Wright, Jr.
patent: 5332669 (1994-07-01), Deuel
patent: 5349066 (1994-09-01), Kaneko et al.
patent: 5391723 (1995-02-01), Priest
patent: 5599685 (1997-02-01), DeFeo-Jones et al.
patent: 5866679 (1999-02-01), DeFeo-Jones et al.
Science, vol. 261, pp. 212-215 (1993) by Trail, et al.
Bioconjugate Chem., vol. 4, pp. 521-527 (1993) by Wilner, et al.
Clin. Biochem., vol. 27, pp. 75-79 (1994) by Yu, et al.
J. Med. Chem., vol. 28, pp. 1079-1088 (1985) by Rao, et al.
J. Med. Chem., vol. 21, No. 21, pp. 88-96 (1978) by Barnett, et al.
J. of Biol. Chem., vol. 264, No. 3, pp. 1894-1900 (1989) by Lilja, et al.
PNAS, vol. 89, pp. 4559-4563 (1992) by Lilja, et al.
Eur. J. Biochem., vol. 194, pp. 755-763 (1990) by Christensen, et al.
PNAS, vol. 83, pp. 3166-3170 (1986) by Watt, et al.
Proc. Natl. Acad. Sci. USA, vol. 83, pp. 3166-3170 (1986) Biochemistry, by Watt, et al.
Eur. J. Biochem., vol. 194, pp. 755-763 (1990), by Christensson, et al.
J. Med. Chem, vol. 26, pp. 633-638 (1983), by Chakravarty, et al.
J. of Med. Chem, vol. 26, No. 5, pp. 638-644 (1983), by Chakravarty, et al.
Eur. J. Biochem, vol. 95, pp. 115-119 (1979), by Pozsgay, et al.
Anal. Biochem., vol. 193, pp. 248-255 (1991), by Harnois-Pontoni, et al.
J. Med. Chem., vol. 34, pp. 3029-3035 (1991), by Mayer, et al.
DeFeo-Jones Deborah
Feng Dong-Mei
Garsky Victor M.
Jones Raymond E.
Oliff Allen I.
Borin Michael
Daniel Mark R.
Merck & Co. , Inc.
Muthard David A.
LandOfFree
Peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2257079